A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 8, 2014

Merck’s Hep C Drugs Show Promise for HIV Coinfection

CROI 2014Promising preliminary results from a trial of Merck’s MK-5172 and MK-8742, given with or without ribavirin, showed that the combination therapy was as safe in treating genotype 1 of hepatitis C virus (HCV) among those coinfected with HIV as it was among those monoinfected with hep C. The treatment appears to boast near-perfect success rates. Results from the C-WORTHY study, which is a Phase II, randomized, dose-responsive, parallel-group, multiple-site, open-label trial comparing various difficult-to-treat populations among a group of 450 people with hep C, were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The coinfected segment of the study included 59 people coinfected with HIV and genotype 1 of HCV who were treatment naive, did not have cirrhosis and who were taking a stable antiretroviral regimen to treat HIV: Isentress (raltegravir) and Viread (tenofovir) or Ziagen (abacavir) with either Epivir (3TC) or Emtriva (emtricitabine ) These participants were compared with 65 people monoinfected with genotype 1 of hep C. All the participants were randomized to receive the NS3/4A protease inhibitor MK-5172 and the NS5A replication complex inhibitor MK-8742 for 12 weeks either with or without ribavirin.

At the end of treatment, all 29 of the coinfected participants who took ribavirin and 90 percent of those who did not (26/29) had undetectable hep C. Meanwhile, among the monoinfected participants, 94 percent of those who took ribavirin (49/52) and all 13 of those who did not achieved an undetectable viral count.

Twelve weeks must pass after the end of treatment for researchers to determine if a participant has been cured of hep C. Merck intends to present such results at a meeting in the spring.

Of the three coinfected participants who failed treatment, one completed the therapy but was then lost to follow-up, and two others maintained low levels of one or both of MK-5172 and MK-8742 and experienced virologic breakthrough at the eight-week mark during treatment.

The most common adverse side effects were fatigue (7 percent) and headache (8 percent). There was no difference in side effects between the coinfected and monoinfected groups.

To read the Merck press release, click here.

Search: Merck, hepatitis C, HCV, coinfection, HIV, MK-5172, MK-8742, C-WORTHY, Isentress, ralegravir, Viread, tenofovir, Ziagen, abacavir, Epivir, 3TC, Emtriva, emtricitabine, monoinfection, CROI


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    guycmh328
    Columbus
    Ohio


    koffeeboss
    Tucson
    Arizona


    OahuAJ
    Glendora
    California


    robert12
    Queens
    New York
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.